Earnings results for Intra-Cellular Therapies (NASDAQ:ITCI)
Intra-Cellular Therapies Inc. is expected* to report earnings on 11/09/2020 before market open. The report will be for the fiscal Quarter ending Sep 2020. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.96. The reported EPS for the same quarter last year was $-0.63.
Intra-Cellular Therapies last announced its quarterly earnings data on August 10th, 2020. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.94) by $0.02. The business had revenue of $1.91 million for the quarter, compared to the consensus estimate of $3.05 million. Intra-Cellular Therapies has generated ($2.68) earnings per share over the last year. Intra-Cellular Therapies has confirmed that its next quarterly earnings report will be published on Monday, November 9th, 2020. Intra-Cellular Therapies will be holding an earnings conference call on Monday, November 9th. Interested parties can register for or listen to the call using this link.
Analyst Opinion on Intra-Cellular Therapies (NASDAQ:ITCI)
7 Wall Street analysts have issued ratings and price targets for Intra-Cellular Therapies in the last 12 months. Their average twelve-month price target is $45.50, predicting that the stock has a possible upside of 86.02%. The high price target for ITCI is $70.00 and the low price target for ITCI is $26.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Intra-Cellular Therapies has received a consensus rating of Buy. The company’s average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings. According to analysts’ consensus price target of $45.50, Intra-Cellular Therapies has a forecasted upside of 86.0% from its current price of $24.46. Intra-Cellular Therapies has only been the subject of 4 research reports in the past 90 days.
Dividend Strength: Intra-Cellular Therapies (NASDAQ:ITCI)
Intra-Cellular Therapies does not currently pay a dividend. Intra-Cellular Therapies does not have a long track record of dividend growth.
Insiders buying/selling: Intra-Cellular Therapies (NASDAQ:ITCI)
In the past three months, Intra-Cellular Therapies insiders have sold 33.31% more of their company’s stock than they have bought. Specifically, they have bought $2,054,880.00 in company stock and sold $2,739,376.00 in company stock. Only 18.20% of the stock of Intra-Cellular Therapies is held by insiders. 71.91% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Intra-Cellular Therapies (NASDAQ:ITCI
Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($3.55) to ($3.05) per share. The P/E ratio of Intra-Cellular Therapies is -7.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Intra-Cellular Therapies is -7.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Intra-Cellular Therapies has a P/B Ratio of 6.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here